LY2140023
- Generic Name
- LY2140023
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- 3V85EZ3KFQ
- Background
LY2140023 is an investigational drug from Lilly, which is being developed as a new treatment option for schizophrenia. LY2140023 is an oral "prodrug," meaning it is devoid of intrinsic biological activity and, once administered, is metabolized to provide the active mGlu2/3 receptor agonist called LY404039. Most currently approved antipsychotic medications wo...
- Indication
Investigated for use/treatment in psychosis and schizophrenia and schizoaffective disorders.
- Associated Conditions
- -
- Associated Therapies
- -
A Study of LY2140023 in Patients With Schizophrenia
- First Posted Date
- 2011-03-03
- Last Posted Date
- 2022-10-18
- Lead Sponsor
- Denovo Biopharma LLC
- Target Recruit Count
- 567
- Registration Number
- NCT01307800
- Locations
- πΊπ¦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vinnytsya, Ukraine
A Long-Term, Open-Label, Study on Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2010-05-25
- Last Posted Date
- 2013-01-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1210
- Registration Number
- NCT01129674
- Locations
- πΊπ¦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vinnytsya, Ukraine
A Study in Schizophrenic Patients
- First Posted Date
- 2010-05-18
- Last Posted Date
- 2021-09-14
- Lead Sponsor
- Denovo Biopharma LLC
- Target Recruit Count
- 82
- Registration Number
- NCT01125358
- Locations
- π¨π³
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan
A Study in Schizophrenia Patients
- First Posted Date
- 2010-03-15
- Last Posted Date
- 2012-09-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 880
- Registration Number
- NCT01086748
- Locations
- π·πΊ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yaroslavl, Russian Federation
A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms
- Conditions
- Interventions
- First Posted Date
- 2010-01-20
- Last Posted Date
- 2022-09-07
- Lead Sponsor
- Denovo Biopharma LLC
- Target Recruit Count
- 167
- Registration Number
- NCT01052103
- Locations
- πͺπΈ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zamora, Spain
A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients
- Conditions
- Interventions
- First Posted Date
- 2009-02-16
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Denovo Biopharma LLC
- Target Recruit Count
- 261
- Registration Number
- NCT00845026
- Locations
- π·πΊ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Samara, Russian Federation
A Study for Patients With Schizophrenia
- First Posted Date
- 2007-08-27
- Last Posted Date
- 2009-10-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 654
- Registration Number
- NCT00520923
- Locations
- πΏπ¦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Randburg, South Africa
Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and Placebo
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2021-08-20
- Lead Sponsor
- Denovo Biopharma LLC
- Target Recruit Count
- 195
- Registration Number
- NCT00149292
- Locations
- π·πΊ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Village Nikolskoe, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.